The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know Webcast (2018)
There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC). The AUA recently released its 2017 report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in this area. Additionally, the findings indicate that the AUA should continue to develop courses and educational materials specifically targeted at residents that covers the medical management of advanced prostate cancer.
The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer (CRPC). Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
The 2018 series is comprised of a variety of activities, including two live forums, four live webinars, webcasts and podcasts. All activities are complimentary.
The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know is the first webcast in a 4-part series. Topics will include "Initial Management and Imaging of Advanced Prostate Cancer" and "Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer ".
This educational series is supported by independent educational grants from:
- Astellas and Pfizer Inc.
- Ferring Pharmaceuticals Inc.
- Genomic Health
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Sanofi Genzyme
- Tolmar Pharmaceuticals, Inc.
- Advanced practice providers
- This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer
At the conclusion of this activity, participants will be able to:
Practice Gap (Disease State)
- Describe the natural course of advanced prostate cancer from non-metastatic to metastatic hormone-sensitive disease, with progression to the development of castration-resistant disease.
- Describe the treatment options and outcomes for newly diagnosed metastatic hormone-sensitive prostate cancer.
Practice Gap (Chemotherapy, Immunotherapy and Co-Morbidity)
- Identify co-morbid states and recognize their impact on treatment options for mCRPC.
Welcome - Michael S. Cookson, MD, MMHC
Initial Management and Imaging of Advanced Prostate Cancer - Todd Matthew Morgan, MD
Chemo-hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer - Alicia Morgans, MD, MPH
Michael S. Cookson, MD, MMHC, FACS: TesoRx Pharma LLC: Consultant or Advisor; Janssen Biotech, Inc.: Consultant or Advisor; MDxHealth: Consultant or Advisor; Bayer Healthcare Pharmaceuticals: Consultant or Advisor
Todd Matthew Morgan, MD: Visible Health, Inc: Leadership Position, Owner, Product Development; Myriad Genetics: Scientific Study or Trial; GenomeDx: Scientific Study or Trial; MdxHealth: Scientific Study or Trial
Alicia Morgans, MD, MPH: Bayer: Consultant or Advisor; Genentech: Consultant or Advisor; Astra Zeneca: Consultant or Advisor; Astellas: Consultant or Advisor; Janssen: Consultant or Advisor; Sanofi: Consultant or Advisor
Method of Participation:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: August, 2018
Expiration Date: August, 2019
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation